1. Home
  2. AIMD vs ENSC Comparison

AIMD vs ENSC Comparison

Compare AIMD & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIMD

Ainos Inc.

HOLD

Current Price

$1.78

Market Cap

10.2M

Sector

Health Care

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$1.01

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIMD
ENSC
Founded
1984
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2M
6.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AIMD
ENSC
Price
$1.78
$1.01
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
23.9K
448.3K
Earning Date
11-13-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$113,037.00
$4,487,973.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
178.19
1.51
52 Week Low
$1.61
$0.86
52 Week High
$5.00
$9.31

Technical Indicators

Market Signals
Indicator
AIMD
ENSC
Relative Strength Index (RSI) 35.05 31.81
Support Level $1.61 $0.89
Resistance Level $1.95 $1.24
Average True Range (ATR) 0.12 0.09
MACD -0.00 0.01
Stochastic Oscillator 26.32 34.13

Price Performance

Historical Comparison
AIMD
ENSC

About AIMD Ainos Inc.

Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: